ANAVEX LIFE SCIENCES CORP. — Director's Dealing 2024

Jan 13, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK: 0001314052
Period of Report: 2024-01-02

Reporting Person: MISSLING CHRISTOPHER U (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-02	Stock Option (Right to Buy)	$10.09	A	125000	Disposed	2032-06-27	Common Stock (125000)	Direct

Footnotes

F1: On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.